샘플 요청 목록

 카트 문의
시장보고서
상품코드
2044618

루푸스 치료제 시장 : 시장 인사이트, 경쟁 구도 및 시장 예측(2033년)

Lupus Therapeutics Market Insights, Competitive Landscape, and Market Forecast - 2033
발행일: | 리서치사: 구분자 Fairfield Market Research | 페이지 정보: 영문 199 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



가격
Unprintable PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.
US $ 4,995 금액 안내 화살표 ￦ 7,680,000
Unprintable PDF & Excel (Multi User License upto 5 users) help
PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.
US $ 8,495 금액 안내 화살표 ￦ 13,062,000
Printable PDF & Excel (Enterprise License above 5 users) help
PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,600 금액 안내 화살표 ￦ 16,299,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 루푸스 치료제 시장은 만성 자가면역질환의 합병증을 관리하고 환자의 예후를 개선하는 효과적인 치료법에 대한 수요가 증가함에 따라 꾸준한 성장세를 보이고 있습니다. 이 시장 규모는 2026년 46억 달러로 평가되었고, 2033년까지 71억 달러에 달할 것으로 예측됩니다. 또한, 예측 기간 동안 CAGR 6.70%를 기록할 전망입니다. 류마티스 질환에 대한 인식 증가, 류마티스 치료 접근성 확대, 표적 치료제의 지속적인 개발로 인해 시장 모멘텀이 강화되고 있습니다. 루푸스는 평생 치료가 필요한 경우가 많기 때문에 의료진은 증상 악화를 억제하고 장기를 보호하며 장기적인 질병 관리를 개선할 수 있는 치료법에 초점을 맞추었습니다.

시장 인사이트

루푸스는 면역체계가 건강한 조직을 공격하여 다양한 장기에 염증과 손상을 일으키는 다면적 자가면역질환입니다. 전신성 홍반성 루푸스, 피부 홍반성 루푸스, 약물 유발성 홍반성 루푸스, 신생아 홍반성 루푸스, 루푸스 신염 등 여러 가지 형태가 있습니다. 그 중에서도 전신성 홍반성 루푸스는 여러 장기에 영향을 미치고 지속적인 모니터링이 필요하기 때문에 여전히 치료 수요의 주요 영역으로 남아있습니다.

시장은 광범위한 증상 관리에서 보다 표적화된 맞춤 치료 접근법으로 전환하고 있습니다. 코르티코스테로이드, 항말라리아제, 면역억제제, 비스테로이드성 항염증제는 여전히 표준 치료에서 중요한 역할을 하고 있습니다. 그러나 의사들이 장기적인 독성을 줄이면서 질병을 더 잘 조절할 수 있는 치료법을 찾고 있는 가운데, 생물학적 제제, B세포 억제제, 칼시뉴린 억제제가 주목받고 있습니다. 이러한 치료 환경의 변화는 자가면역질환 및 염증성 질환 포트폴리오에 집중하는 기업들에게 새로운 기회를 창출하고 있습니다.

성장 촉진요인

루푸스 치료제 시장의 주요 시장 성장 촉진요인은 자가면역질환의 유병률 증가와 전문의의 치료를 받는 환자 수 증가입니다. 환자와 의사들의 인식이 높아지면서 특히 다른 만성 염증성 질환과 증상이 중복되는 경우 진단율 향상에 기여하고 있습니다. 조기 진단을 통해 적시에 치료할 수 있어 심각한 질병의 진행과 장기 침범의 위험을 줄일 수 있습니다.

또 다른 중요한 촉진요인은 장기적인 코르티코스테로이드 사용에 대한 의존도를 줄여야 할 필요성이 증가하고 있다는 점입니다. 코르티코스테로이드는 여전히 염증 억제에 효과적이지만, 장기간 사용하면 심각한 부작용이 발생할 수 있습니다. 이 때문에 스테로이드 절약 요법이나 표적 치료제의 채택이 진행되고 있습니다. 또한, 생물학적 제제 및 면역학 연구의 발전은 루푸스에 관여하는 특정 면역 경로에 작용하도록 설계된 치료법 개발을 뒷받침하고 있습니다.

비즈니스 기회

이 시장은 제약회사, 생명공학 기업, 전문 약국 및 의료 서비스 제공업체에게 큰 비즈니스 기회를 제공합니다. 루푸스 신염, 전신성 홍반성 루푸스, 난치성 루푸스 환자들을 위한 차별화된 치료제를 개발하는 기업은 경쟁 우위를 확보할 수 있을 것입니다. 안전성 향상, 지속적 효과, 투약 편의성, 병용요법과의 궁합이 잘 맞는 제품은 의사와 환자들의 관심이 더욱 높아질 것으로 예측됩니다.

전문약국은 첨단 치료에 대한 접근성을 지원하는 데 있어 점점 더 중요한 역할을 할 것으로 예측됩니다. 이러한 채널은 환자 교육, 복약 순응도 프로그램, 보험 상환 지원, 치료 모니터링 지원을 제공할 수 있습니다. 또한, 환자들이 만성질환 치료제에 대한 편리한 접근을 원함에 따라 온라인 약국의 중요성도 커지고 있습니다. 또한, 제약사, 학계, 환자 지원 단체 간의 협력은 임상시험 대상자 모집을 개선하고 치료법 혁신을 가속화하는 데 도움이 될 수 있습니다.

지역별 분석

북미는 높은 의료 인프라, 자가면역질환에 대한 높은 인식, 그리고 혁신적인 치료법의 적극적인 도입으로 루푸스 치료제 시장에서 중요한 위치를 차지할 것으로 예측됩니다. 또한, 이 지역은 대형 제약회사의 존재, 활발한 임상 연구, 그리고 잘 구축된 전문 의료 네트워크의 혜택을 누리고 있습니다.

유럽은 체계화된 의료 시스템, 생물학적 제제 사용 확대, 자가면역질환 관리에 대한 관심 증가에 힘입어 또 다른 중요한 시장으로 부상하고 있습니다. 아시아태평양은 진단 능력의 향상과 전문 클리닉에 대한 접근성 확대에 따라 괄목할 만한 성장 잠재력을 보일 것으로 예측됩니다. 의료비 증가, 의료에 대한 인식 증가, 그리고 방대한 환자 수는 이 지역의 주요 국가에서 시장 발전을 뒷받침할 것으로 예측됩니다. 라틴아메리카와 중동 및 아프리카에서도 의료 시스템이 만성 질환 치료와 전문의 진료에 대한 접근성을 확대함에 따라 상황이 점차 개선되고 있습니다.

시장 전망

루푸스 치료제 시장 전망은 혁신, 환자 중심의 치료, 첨단 치료 옵션에 대한 접근성 향상으로 형성될 것입니다. 루푸스에 대한 임상적 이해가 계속 발전함에 따라, 치료법 선택은 질환의 유형, 중증도, 장기 침범 여부, 환자의 반응에 따라 더욱 개별화되고 있습니다. 이러한 추세에 따라 일관된 질병 조절과 합병증을 줄일 수 있는 표적치료제에 대한 수요가 증가할 것으로 예측됩니다.

제약사들은 시장에서의 입지를 강화하기 위해 임상적 차별화, 실제 데이터, 적응증 확대에 집중할 가능성이 높습니다. 또한, 치료법의 보급 확대를 위해서는 환자 지원 프로그램, 가격 접근성, 유통망 개선도 중요합니다. 루푸스는 장기적인 관리가 필요하기 때문에 효과적인 치료와 복약 순응도 지원, 전문의의 진료 조정을 결합할 수 있는 이해관계자는 향후 성장에 유리한 고지를 점할 수 있을 것입니다.

주요 기업

루푸스 치료제 시장에는 자가면역질환 치료, 생물학적 제제, 면역학 연구 및 전문 치료제에 투자하는 여러 세계 기업들이 포함되어 있습니다. 주요 기업은 다음과 같습니다.

  • GSK plc
  • AstraZeneca PLC
  • Aurinia Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Novartis AG
  • Eli Lilly and Company
  • Bristol Myers Squibb Company
  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Johnson & Johnson
  • UCB S.A.
  • Viatris Inc.

세분화

질병 유형별

  • 전신성 홍반성 루푸스
  • 피부 홍반성 루푸스
  • 약물성 루푸스
  • 신생아 루푸스
  • 루푸스 신염
  • 기타

약제 유형별

  • 코르티코스테로이드
  • 항말라리아제
  • 면역억제제
  • 생물학적 제제
  • 비스테로이드성 항염증제
  • B세포 억제제
  • 칼시뉴린 억제제
  • 기타

유통채널별

  • 병원 약국
  • 일반약국
  • 전문약국
  • 온라인 약국

최종 사용자별

  • 병원
  • 전문 클리닉
  • 류마티스 내과 클리닉
  • 피부과 클리닉
  • 외래수술센터
  • 기타

지역별

  • 북미
  • 북미
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

목차

제1장 주요 요약

제2장 시장 개요

제3장 세계의 루푸스 치료제 시장 전망, 2020년-2033년

제4장 북미의 루푸스 치료제 시장 전망, 2020년-2033년

제5장 유럽의 루푸스 치료제 시장 전망, 2020년-2033년

제6장 아시아태평양의 루푸스 치료제 시장 전망, 2020년-2033년

제7장 라틴아메리카의 루푸스 치료제 시장 전망, 2020년-2033년

제8장 중동 및 아프리카의 루푸스 치료제 시장 전망, 2020년-2033년

제9장 경쟁 구도

제10장 부록

LSH 26.06.08

The global Lupus Therapeutics Market is witnessing consistent growth as demand rises for effective treatment options that help manage chronic autoimmune complications and improve patient outcomes. The market is valued at US$ 4.6 Bn in 2026 and is projected to reach US$ 7.1 Bn by 2033, growing at a CAGR of 6.70% during the forecast period. Increasing disease awareness, expanding access to rheumatology care, and continued development of targeted therapies are strengthening market momentum. As lupus often requires lifelong treatment, healthcare providers are focusing on therapies that reduce flare-ups, protect organs, and support better long-term disease control.

Market Insights

Lupus is a multifaceted autoimmune disorder in which the immune system attacks healthy tissues, leading to inflammation and damage across different organs. The disease can appear in several forms, including systemic lupus erythematosus, cutaneous lupus erythematosus, drug-induced lupus, neonatal lupus, and lupus nephritis. Among these, systemic lupus erythematosus remains a major area of treatment demand because it can affect multiple organ systems and requires continuous monitoring.

The market is shifting from broad symptom management toward more targeted and personalized treatment approaches. Corticosteroids, antimalarials, immunosuppressants, and nonsteroidal anti-inflammatory drugs continue to play an important role in standard care. However, biologics, B-cell inhibitors, and calcineurin inhibitors are gaining attention as physicians seek therapies that offer better disease control with reduced long-term toxicity. This changing treatment landscape is creating new opportunities for companies focused on autoimmune and inflammatory disease portfolios.

Drivers

A major driver for the Lupus Therapeutics Market is the growing prevalence of autoimmune disorders and the increasing number of patients seeking specialist care. Greater awareness among patients and physicians is helping improve diagnosis rates, especially in cases where symptoms overlap with other chronic inflammatory conditions. Early diagnosis enables timely treatment, reducing the risk of severe disease progression and organ involvement.

Another important driver is the rising need to reduce dependence on long-term corticosteroid use. While corticosteroids remain effective for controlling inflammation, prolonged use can be associated with significant side effects. This has encouraged the adoption of steroid-sparing therapies and targeted drug classes. Advancements in biologics and immunology research are also supporting the development of therapies designed to address specific immune pathways involved in lupus.

Business Opportunity

The market offers strong business opportunities for pharmaceutical manufacturers, biotechnology companies, specialty pharmacies, and healthcare service providers. Companies developing differentiated therapies for lupus nephritis, systemic lupus erythematosus, and refractory lupus cases can gain a competitive advantage. Products that demonstrate improved safety, durable response, convenient dosing, and compatibility with combination therapy are likely to attract greater physician and patient interest.

Specialty pharmacies are expected to play an increasingly important role in supporting access to advanced therapies. These channels can provide patient education, adherence programs, reimbursement assistance, and treatment monitoring support. Online pharmacies are also gaining relevance as patients seek convenient access to chronic disease medications. In addition, collaborations between drug developers, academic centers, and patient advocacy groups can help improve clinical trial recruitment and accelerate therapy innovation.

Region Analysis

North America is expected to hold a significant position in the Lupus Therapeutics Market due to advanced healthcare infrastructure, high awareness of autoimmune diseases, and strong adoption of innovative treatments. The region also benefits from the presence of major pharmaceutical companies, active clinical research, and well-established specialty care networks.

Europe represents another important market, supported by structured healthcare systems, increasing use of biologics, and growing focus on autoimmune disease management. Asia Pacific is likely to show notable growth potential as diagnostic capabilities improve and access to specialty clinics expands. Rising healthcare expenditure, increasing awareness, and a large patient population are expected to support market development across key countries in the region. Latin America and the Middle East & Africa are also witnessing gradual improvement as healthcare systems expand access to chronic disease therapies and specialist consultation.

Market Outlook

The future of the Lupus Therapeutics Market will be shaped by innovation, patient-centered care, and improved access to advanced treatment options. As clinical understanding of lupus continues to evolve, therapy selection is becoming more individualized based on disease type, severity, organ involvement, and patient response. This trend is expected to increase demand for targeted therapies that can deliver consistent disease control and reduce complications.

Pharmaceutical companies are likely to focus on clinical differentiation, real-world evidence, and expanded indications to strengthen market presence. Patient support programs, affordability initiatives, and improved distribution networks will also be important for broader therapy adoption. With lupus requiring long-term management, stakeholders that can combine effective treatment with adherence support and specialist care coordination will be well positioned for future growth.

Key Players

The Lupus Therapeutics Market includes several global companies investing in autoimmune disease treatment, biologics, immunology research, and specialty therapeutics. Key players include:

  • GSK plc
  • AstraZeneca PLC
  • Aurinia Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Novartis AG
  • Eli Lilly and Company
  • Bristol Myers Squibb Company
  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Johnson & Johnson
  • UCB S.A.
  • Viatris Inc.

Segmentation

By Disease Type

  • Systemic Lupus Erythematosus
  • Cutaneous Lupus Erythematosus
  • Drug-induced Lupus
  • Neonatal Lupus
  • Lupus Nephritis
  • Others

By Drug Class

  • Corticosteroids
  • Antimalarials
  • Immunosuppressants
  • Biologics
  • Nonsteroidal Anti-inflammatory Drugs
  • B-cell Inhibitors
  • Calcineurin Inhibitors
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies

By End User

  • Hospitals
  • Specialty Clinics
  • Rheumatology Clinics
  • Dermatology Clinics
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Lupus Therapeutics Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Lupus Therapeutics Market Outlook, 2020 - 2033

  • 3.1. Global Lupus Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Systemic Lupus Erythematosus
    • 3.1.2. Cutaneous Lupus Erythematosus
    • 3.1.3. Drug-induced Lupus
    • 3.1.4. Neonatal Lupus
    • 3.1.5. Lupus Nephritis
    • 3.1.6. Others
  • 3.2. Global Lupus Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 3.2.1. Corticosteroids
    • 3.2.2. Antimalarials
    • 3.2.3. Immunosuppressants
    • 3.2.4. Biologics
    • 3.2.5. Nonsteroidal Anti-inflammatory Drugs
    • 3.2.6. B-cell Inhibitors
    • 3.2.7. Calcineurin Inhibitors
    • 3.2.8. Others
  • 3.3. Global Lupus Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.3.1. Hospital Pharmacies
    • 3.3.2. Retail Pharmacies
    • 3.3.3. Specialty Pharmacies
    • 3.3.4. Online Pharmacies
  • 3.4. Global Lupus Therapeutics Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.4.1. Hospitals
    • 3.4.2. Specialty Clinics
    • 3.4.3. Rheumatology Clinics
    • 3.4.4. Dermatology Clinics
    • 3.4.5. Ambulatory Surgical Centers
    • 3.4.6. Others
  • 3.5. Global Lupus Therapeutics Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.5.1. North America
    • 3.5.2. Europe
    • 3.5.3. Asia Pacific
    • 3.5.4. Latin America
    • 3.5.5. Middle East & Africa

4. North America Lupus Therapeutics Market Outlook, 2020 - 2033

  • 4.1. North America Lupus Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Systemic Lupus Erythematosus
    • 4.1.2. Cutaneous Lupus Erythematosus
    • 4.1.3. Drug-induced Lupus
    • 4.1.4. Neonatal Lupus
    • 4.1.5. Lupus Nephritis
    • 4.1.6. Others
  • 4.2. North America Lupus Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 4.2.1. Corticosteroids
    • 4.2.2. Antimalarials
    • 4.2.3. Immunosuppressants
    • 4.2.4. Biologics
    • 4.2.5. Nonsteroidal Anti-inflammatory Drugs
    • 4.2.6. B-cell Inhibitors
    • 4.2.7. Calcineurin Inhibitors
    • 4.2.8. Others
  • 4.3. North America Lupus Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies
    • 4.3.3. Specialty Pharmacies
    • 4.3.4. Online Pharmacies
  • 4.4. North America Lupus Therapeutics Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.4.1. Hospitals
    • 4.4.2. Specialty Clinics
    • 4.4.3. Rheumatology Clinics
    • 4.4.4. Dermatology Clinics
    • 4.4.5. Ambulatory Surgical Centers
    • 4.4.6. Others
  • 4.5. North America Lupus Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.5.1. U.S. Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 4.5.2. U.S. Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 4.5.3. U.S. Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 4.5.4. U.S. Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 4.5.5. Canada Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 4.5.6. Canada Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 4.5.7. Canada Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 4.5.8. Canada Lupus Therapeutics Market Outlook, by End User, 2020-2033
  • 4.6. BPS Analysis/Market Attractiveness Analysis

5. Europe Lupus Therapeutics Market Outlook, 2020 - 2033

  • 5.1. Europe Lupus Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Systemic Lupus Erythematosus
    • 5.1.2. Cutaneous Lupus Erythematosus
    • 5.1.3. Drug-induced Lupus
    • 5.1.4. Neonatal Lupus
    • 5.1.5. Lupus Nephritis
    • 5.1.6. Others
  • 5.2. Europe Lupus Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 5.2.1. Corticosteroids
    • 5.2.2. Antimalarials
    • 5.2.3. Immunosuppressants
    • 5.2.4. Biologics
    • 5.2.5. Nonsteroidal Anti-inflammatory Drugs
    • 5.2.6. B-cell Inhibitors
    • 5.2.7. Calcineurin Inhibitors
    • 5.2.8. Others
  • 5.3. Europe Lupus Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies
    • 5.3.3. Specialty Pharmacies
    • 5.3.4. Online Pharmacies
  • 5.4. Europe Lupus Therapeutics Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.4.1. Hospitals
    • 5.4.2. Specialty Clinics
    • 5.4.3. Rheumatology Clinics
    • 5.4.4. Dermatology Clinics
    • 5.4.5. Ambulatory Surgical Centers
    • 5.4.6. Others
  • 5.5. Europe Lupus Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.5.1. Germany Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.2. Germany Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.3. Germany Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.4. Germany Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 5.5.5. Italy Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.6. Italy Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.7. Italy Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.8. Italy Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 5.5.9. France Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.10. France Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.11. France Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.12. France Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 5.5.13. U.K. Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.14. U.K. Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.15. U.K. Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.16. U.K. Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 5.5.17. Spain Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.18. Spain Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.19. Spain Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.20. Spain Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 5.5.21. Russia Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.22. Russia Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.23. Russia Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.24. Russia Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 5.5.25. Rest of Europe Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 5.5.26. Rest of Europe Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 5.5.27. Rest of Europe Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.28. Rest of Europe Lupus Therapeutics Market Outlook, by End User, 2020-2033
  • 5.6. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Lupus Therapeutics Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Lupus Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Systemic Lupus Erythematosus
    • 6.1.2. Cutaneous Lupus Erythematosus
    • 6.1.3. Drug-induced Lupus
    • 6.1.4. Neonatal Lupus
    • 6.1.5. Lupus Nephritis
    • 6.1.6. Others
  • 6.2. Asia Pacific Lupus Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 6.2.1. Corticosteroids
    • 6.2.2. Antimalarials
    • 6.2.3. Immunosuppressants
    • 6.2.4. Biologics
    • 6.2.5. Nonsteroidal Anti-inflammatory Drugs
    • 6.2.6. B-cell Inhibitors
    • 6.2.7. Calcineurin Inhibitors
    • 6.2.8. Others
  • 6.3. Asia Pacific Lupus Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Specialty Pharmacies
    • 6.3.4. Online Pharmacies
  • 6.4. Asia Pacific Lupus Therapeutics Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.4.1. Hospitals
    • 6.4.2. Specialty Clinics
    • 6.4.3. Rheumatology Clinics
    • 6.4.4. Dermatology Clinics
    • 6.4.5. Ambulatory Surgical Centers
    • 6.4.6. Others
  • 6.5. Asia Pacific Lupus Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.5.1. China Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 6.5.2. China Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 6.5.3. China Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.4. China Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 6.5.5. Japan Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 6.5.6. Japan Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 6.5.7. Japan Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.8. Japan Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 6.5.9. South Korea Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 6.5.10. South Korea Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 6.5.11. South Korea Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.12. South Korea Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 6.5.13. India Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 6.5.14. India Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 6.5.15. India Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.16. India Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 6.5.17. Southeast Asia Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 6.5.18. Southeast Asia Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 6.5.19. Southeast Asia Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.20. Southeast Asia Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 6.5.21. Rest of SAO Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 6.5.22. Rest of SAO Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 6.5.23. Rest of SAO Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.24. Rest of SAO Lupus Therapeutics Market Outlook, by End User, 2020-2033
  • 6.6. BPS Analysis/Market Attractiveness Analysis

7. Latin America Lupus Therapeutics Market Outlook, 2020 - 2033

  • 7.1. Latin America Lupus Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Systemic Lupus Erythematosus
    • 7.1.2. Cutaneous Lupus Erythematosus
    • 7.1.3. Drug-induced Lupus
    • 7.1.4. Neonatal Lupus
    • 7.1.5. Lupus Nephritis
    • 7.1.6. Others
  • 7.2. Latin America Lupus Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 7.2.1. Corticosteroids
    • 7.2.2. Antimalarials
    • 7.2.3. Immunosuppressants
    • 7.2.4. Biologics
    • 7.2.5. Nonsteroidal Anti-inflammatory Drugs
    • 7.2.6. B-cell Inhibitors
    • 7.2.7. Calcineurin Inhibitors
    • 7.2.8. Others
  • 7.3. Latin America Lupus Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Specialty Pharmacies
    • 7.3.4. Online Pharmacies
  • 7.4. Latin America Lupus Therapeutics Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.4.1. Hospitals
    • 7.4.2. Specialty Clinics
    • 7.4.3. Rheumatology Clinics
    • 7.4.4. Dermatology Clinics
    • 7.4.5. Ambulatory Surgical Centers
    • 7.4.6. Others
  • 7.5. Latin America Lupus Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.5.1. Brazil Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 7.5.2. Brazil Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 7.5.3. Brazil Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 7.5.4. Brazil Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 7.5.5. Mexico Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 7.5.6. Mexico Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 7.5.7. Mexico Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 7.5.8. Mexico Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 7.5.9. Argentina Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 7.5.10. Argentina Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 7.5.11. Argentina Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 7.5.12. Argentina Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 7.5.13. Rest of LATAM Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 7.5.14. Rest of LATAM Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 7.5.15. Rest of LATAM Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 7.5.16. Rest of LATAM Lupus Therapeutics Market Outlook, by End User, 2020-2033
  • 7.6. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Lupus Therapeutics Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Lupus Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Systemic Lupus Erythematosus
    • 8.1.2. Cutaneous Lupus Erythematosus
    • 8.1.3. Drug-induced Lupus
    • 8.1.4. Neonatal Lupus
    • 8.1.5. Lupus Nephritis
    • 8.1.6. Others
  • 8.2. Middle East & Africa Lupus Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 8.2.1. Corticosteroids
    • 8.2.2. Antimalarials
    • 8.2.3. Immunosuppressants
    • 8.2.4. Biologics
    • 8.2.5. Nonsteroidal Anti-inflammatory Drugs
    • 8.2.6. B-cell Inhibitors
    • 8.2.7. Calcineurin Inhibitors
    • 8.2.8. Others
  • 8.3. Middle East & Africa Lupus Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Specialty Pharmacies
    • 8.3.4. Online Pharmacies
  • 8.4. Middle East & Africa Lupus Therapeutics Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.4.1. Hospitals
    • 8.4.2. Specialty Clinics
    • 8.4.3. Rheumatology Clinics
    • 8.4.4. Dermatology Clinics
    • 8.4.5. Ambulatory Surgical Centers
    • 8.4.6. Others
  • 8.5. Middle East & Africa Lupus Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.5.1. GCC Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 8.5.2. GCC Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 8.5.3. GCC Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.4. GCC Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 8.5.5. South Africa Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 8.5.6. South Africa Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 8.5.7. South Africa Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.8. South Africa Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 8.5.9. Egypt Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 8.5.10. Egypt Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 8.5.11. Egypt Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.12. Egypt Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 8.5.13. Nigeria Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 8.5.14. Nigeria Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 8.5.15. Nigeria Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.16. Nigeria Lupus Therapeutics Market Outlook, by End User, 2020-2033
    • 8.5.17. Rest of Middle East Lupus Therapeutics Market Outlook, by Disease Type, 2020-2033
    • 8.5.18. Rest of Middle East Lupus Therapeutics Market Outlook, by Drug Class, 2020-2033
    • 8.5.19. Rest of Middle East Lupus Therapeutics Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.20. Rest of Middle East Lupus Therapeutics Market Outlook, by End User, 2020-2033
  • 8.6. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. GSK plc
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. AstraZeneca PLC
    • 9.4.3. Aurinia Pharmaceuticals Inc.
    • 9.4.4. F. Hoffmann-La Roche Ltd.
    • 9.4.5. Pfizer Inc.
    • 9.4.6. Sanofi S.A.
    • 9.4.7. Novartis AG
    • 9.4.8. Eli Lilly and Company
    • 9.4.9. Bristol Myers Squibb Company
    • 9.4.10. AbbVie Inc.
    • 9.4.11. Amgen Inc.
    • 9.4.12. Biogen Inc.
    • 9.4.13. Johnson & Johnson
    • 9.4.14. UCB S.A.
    • 9.4.15. Viatris Inc.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기